Activation of the mitogen-activated protein kinase-extracellular signal-regulated kinase pathway in childhood B-cell acute lymphoblastic leukemia. 2022

Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
Department of Pediatrics, Division of Pediatric Hematology-Oncology, Mount Sinai Kravis Children's Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

RAS mutations are frequently observed in childhood B-cell acute lymphoblastic leukemia (B-ALL) and previous studies have yielded conflicting results as to whether they are associated with a poor outcome. We and others have demonstrated that the mitogen-activated protein kinase-extracellular signal-regulated kinase (MAPK) pathway can be activated through epigenetic mechanisms in the absence of RAS pathway mutations. Herein, we examined whether MAPK activation, as determined by measuring phosphorylated extracellular signal-regulated kinase (pERK) levels in 80 diagnostic patient samples using phosphoflow cytometry, could be used as a prognostic biomarker for pediatric B-ALL. The mean fluorescence intensity of pERK (MFI) was measured at baseline and after exogenous stimulation with or without pretreatment with the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib. Activation levels (MFI stimulated/MFI baseline) ranged from 0.76 to 4.40 (median = 1.26), and inhibition indexes (MFI stimulated/MFI trametinib stimulated) ranged from 0.439 to 5.640 (median = 1.30), with no significant difference between patients with wildtype versus mutant RAS for either. Logistic regression demonstrated that neither MAPK activation levels nor RAS mutation status at diagnosis alone or in combination was prognostic of outcome. However, 35% of RAS wildtype samples showed MAPK inhibition indexes greater than the median, thus raising the possibility that therapeutic strategies to inhibit MAPK activation may not be restricted to patients whose blasts display Ras pathway defects.

UI MeSH Term Description Entries
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016393 Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. B-Cell Lymphoma,B Cell Lymphoma,B-Cell Lymphomas,Lymphoma, B Cell,Lymphomas, B-Cell
D048049 Extracellular Signal-Regulated MAP Kinases A mitogen-activated protein kinase subfamily that is widely expressed and plays a role in regulation of MEIOSIS; MITOSIS; and post mitotic functions in differentiated cells. The extracellular signal regulated MAP kinases are regulated by a broad variety of CELL SURFACE RECEPTORS and can be activated by certain CARCINOGENS. ERK MAP Kinase,ERK MAP Kinases,Extracellular Signal-Regulated Kinase,Extracellular Signal-Regulated Kinases,Extracellular Signal-Regulated MAP Kinase,MAP Kinases, Extracellular Signal-Regulated,Extracellular Signal Regulated Kinase,Extracellular Signal Regulated Kinases,Extracellular Signal Regulated MAP Kinase,Extracellular Signal Regulated MAP Kinases,Kinase, ERK MAP,Kinase, Extracellular Signal-Regulated,Kinases, Extracellular Signal-Regulated,MAP Kinase, ERK,MAP Kinases, Extracellular Signal Regulated,Signal-Regulated Kinase, Extracellular
D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Leukemia, Lymphoblastic,Leukemia, Lymphoid, Acute,Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Lymphocytic Leukemia, Acute,Lymphoma, Lymphoblastic,ALL, Childhood,Acute Lymphoid Leukemia,Leukemia, Acute Lymphoblastic,Leukemia, Lymphoblastic, Acute,Leukemia, Lymphoblastic, Acute, L1,Leukemia, Lymphoblastic, Acute, L2,Leukemia, Lymphoblastic, Acute, Philadelphia-Positive,Leukemia, Lymphocytic, Acute,Leukemia, Lymphocytic, Acute, L1,Leukemia, Lymphocytic, Acute, L2,Lymphoblastic Leukemia, Acute,Lymphoblastic Leukemia, Acute, Adult,Lymphoblastic Leukemia, Acute, Childhood,Lymphoblastic Leukemia, Acute, L1,Lymphoblastic Leukemia, Acute, L2,Lymphocytic Leukemia, L1,Lymphocytic Leukemia, L2,Acute Lymphoblastic Leukemia,Acute Lymphocytic Leukemia,Childhood ALL,L1 Lymphocytic Leukemia,L2 Lymphocytic Leukemia,Leukemia, Acute Lymphocytic,Leukemia, Acute Lymphoid,Leukemia, L1 Lymphocytic,Leukemia, L2 Lymphocytic,Lymphoid Leukemia, Acute,Precursor Cell Lymphoblastic Leukemia Lymphoma
D020929 Mitogen-Activated Protein Kinase Kinases A dual-specific protein kinase family whose members are components in protein kinase cascades activated by diverse stimuli. These MAPK kinases phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES and are themselves phosphorylated by MAP KINASE KINASE KINASES. JNK kinases (also known as SAPK kinases) are a subfamily. MAP Kinase Kinases,MAPK Kinase,MAPK Kinases,MAPK-ERK Kinase,MAPK-ERK Kinases,MAPKKs,MEK,MEKs,Mitogen-Activated Protein Kinase Kinase,MAP-ERK Kinase,MAPKK,Map Kinase Kinase,Kinase Kinase, Map,Kinase Kinases, MAP,Kinase, MAP-ERK,Kinase, MAPK,Kinase, MAPK-ERK,Kinase, Map Kinase,Kinases, MAP Kinase,Kinases, MAPK,Kinases, MAPK-ERK,MAP ERK Kinase,MAPK ERK Kinase,MAPK ERK Kinases,Mitogen Activated Protein Kinase Kinase,Mitogen Activated Protein Kinase Kinases
D020935 MAP Kinase Signaling System An intracellular signaling system involving the mitogen-activated protein kinase cascades (three-membered protein kinase cascades). Various upstream activators, which act in response to extracellular stimuli, trigger the cascades by activating the first member of a cascade, MAP KINASE KINASE KINASES; (MAPKKKs). Activated MAPKKKs phosphorylate MITOGEN-ACTIVATED PROTEIN KINASE KINASES which in turn phosphorylate the MITOGEN-ACTIVATED PROTEIN KINASES; (MAPKs). The MAPKs then act on various downstream targets to affect gene expression. In mammals, there are several distinct MAP kinase pathways including the ERK (extracellular signal-regulated kinase) pathway, the SAPK/JNK (stress-activated protein kinase/c-jun kinase) pathway, and the p38 kinase pathway. There is some sharing of components among the pathways depending on which stimulus originates activation of the cascade. MAP Kinase Cascade,MAP Kinase Module,MAP Kinase Signaling Cascade,MAP Kinase Signaling Pathway,MAP Kinase Signaling Pathways,ERK Pathway,ERK Signal Tranduction Pathway,ERK1 and ERK2 Pathway,ERK1-2 Pathway,JNK Pathway,JNK Signaling Pathway,MAP Kinase Modules,MAP Kinase Signaling Cascades,MEK-ERK Pathway,p38 Kinase Pathway,p38 Kinase Signaling Pathway,Cascade, MAP Kinase,ERK Pathways,ERK1 2 Pathway,ERK1-2 Pathways,JNK Pathways,JNK Signaling Pathways,Kinase Cascade, MAP,Kinase Pathway, p38,Kinase Pathways, p38,MAP Kinase Cascades,MEK ERK Pathway,MEK-ERK Pathways,Module, MAP Kinase,Pathway, ERK,Pathway, ERK1-2,Pathway, JNK,Pathway, JNK Signaling,Pathway, MEK-ERK,Pathway, p38 Kinase,Pathways, ERK,Pathways, ERK1-2,Pathways, JNK,Pathways, JNK Signaling,Pathways, MEK-ERK,Pathways, p38 Kinase,Signaling Pathway, JNK,Signaling Pathways, JNK,p38 Kinase Pathways

Related Publications

Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
February 2022, Journal of bone metabolism,
Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
September 2002, Molecular biology of the cell,
Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
May 2003, International journal of hematology,
Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
October 2008, Clinical cancer research : an official journal of the American Association for Cancer Research,
Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
July 2003, Cancer research,
Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
September 2008, Acta pharmacologica Sinica,
Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
July 2012, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
February 1998, Molecular and cellular biology,
Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
January 2020, Cancer research,
Pallavi M Pillai, and Nicole Mallory, and Joanna Pierro, and Jason Saliba, and Daniel Newman, and Jiyuan Hu, and Teena Bhatla, and Elizabeth Raetz, and William L Carroll, and Nikki A Evensen
November 2011, Neuroreport,
Copied contents to your clipboard!